Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00829296

Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries (EFFORT)

The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics

Sponsor: Forest Laboratories

Updated 6 times since 2017 Last updated: Jan 8, 2016 Started: Jan 31, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Diabetes and Hypertension and is currently completed. Forest Laboratories leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States